252 related articles for article (PubMed ID: 36046748)
1. A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology.
Yin X; Li J; Hao Z; Ding R; Qiao Y
Front Cell Infect Microbiol; 2022; 12():964469. PubMed ID: 36046748
[TBL] [Abstract][Full Text] [Related]
2. A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification.
Li S; Hao L; Hu X; Li L
Infect Agent Cancer; 2023 Jul; 18(1):41. PubMed ID: 37393234
[TBL] [Abstract][Full Text] [Related]
3. Exploring the effect of Gupi Xiaoji Prescription on hepatitis B virus-related liver cancer through network pharmacology and in vitro experiments.
Yu S; Gao W; Zeng P; Chen C; Zhang Z; Liu Z; Liu J
Biomed Pharmacother; 2021 Jul; 139():111612. PubMed ID: 33915505
[TBL] [Abstract][Full Text] [Related]
4. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma.
Yuan L; Bing Z; Han J; An X; Liu X; Li R; Wang C; Sun X; Yang L; Yang K
Biomed Pharmacother; 2020 Apr; 124():109838. PubMed ID: 31981943
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic.
Yan SY; Fan JG; Qio L
Curr Cancer Drug Targets; 2017; 17(6):505-511. PubMed ID: 27677954
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.
Jang JW
World J Gastroenterol; 2014 Jun; 20(24):7675-85. PubMed ID: 24976705
[TBL] [Abstract][Full Text] [Related]
7. A large-scale transcriptional analysis reveals herb-derived ginsenoside F2 suppressing hepatocellular carcinoma via inhibiting STAT3.
Tan X; Ma X; Dai Y; An J; Yu X; Li S; Liao Y; Pei T; Tang Y; Gui Y; Zhou S; Guo D; Deng Y; Hu K; Wang D
Phytomedicine; 2023 Nov; 120():155031. PubMed ID: 37666060
[TBL] [Abstract][Full Text] [Related]
8. Exploring the mechanisms underlying the therapeutic effect of the
Qing L; Pan B; He Y; Liu Y; Zhao M; Niu B; Gao X
Aging (Albany NY); 2022 Nov; 14(22):9103-9127. PubMed ID: 36403263
[TBL] [Abstract][Full Text] [Related]
9. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS
Pei T; Dai Y; Tan X; Geng A; Li S; Gui Y; Hu C; An J; Yu X; Bao X; Wang D
J Ethnopharmacol; 2023 Apr; 306():116134. PubMed ID: 36627003
[TBL] [Abstract][Full Text] [Related]
10. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.
Hu Y; Wang S; Wu X; Zhang J; Chen R; Chen M; Wang Y
J Ethnopharmacol; 2013 Oct; 149(3):601-12. PubMed ID: 23916858
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.
Yu M; Xu W; Jie Y; Pang J; Huang S; Cao J; Gong J; Li X; Chong Y
World J Surg Oncol; 2021 Mar; 19(1):66. PubMed ID: 33685467
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
Yu SJ; Kim YJ
World J Gastroenterol; 2014 Sep; 20(34):12039-44. PubMed ID: 25232241
[TBL] [Abstract][Full Text] [Related]
14. Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology.
Wu Z; Wei C; Wang L; He L
Evid Based Complement Alternat Med; 2021; 2021():9991533. PubMed ID: 34306165
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
16. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
[TBL] [Abstract][Full Text] [Related]
17. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
18. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma.
Morishita A; Fujita K; Iwama H; Chiyo T; Fujihara S; Oura K; Tadokoro T; Mimura S; Nomura T; Tani J; Yoneyama H; Kobayashi K; Kamada H; Guan Y; Nishiyama A; Okano K; Suzuki Y; Himoto T; Shimotohno K; Masaki T
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G401-G409. PubMed ID: 31905024
[TBL] [Abstract][Full Text] [Related]
19. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
